D. Ukena

发表

18F-FDG PET for Mediastinal Staging of Lung Cancer: Which SUV Threshold Makes Sense?

D. Hellwig, C. Kirsch, A. Groeschel, 2007, Journal of Nuclear Medicine.

Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer.

N. Willich, C. Rübe, Michael Thomas, 2008, The Lancet. Oncology.

18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis.

K Schnabel, U Nestle, U. Nestle, 1999, International journal of radiation oncology, biology, physics.

Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma.

H. Schäfers, D. Hellwig, C. Kirsch, 2004, The Journal of thoracic and cardiovascular surgery.

[Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000].

D. Hellwig, C. Kirsch, F. Paulsen, 2001, Pneumologie.

Zardaverine as a selective inhibitor of phosphodiesterase isozymes.

D. Ukena, C. Schudt, S. Winder, 1991, Biochemical pharmacology.

Value of FDG PET in the management of NSCLC.

D. Hellwig, D. Ukena, 2004, Lung cancer.

A palliative accelerated irradiation regimen for advanced non-small-lung-cancer versus conventionally fractionated 60 Gy: results of randomised equivalence study

U. Abel, U. Nestle, C. Nieder, 2001 .

[18FDG in the primary staging of lung tumors. Results with a gamma camera and a 511 keV collimator].

C. Alexander, G. Sybrecht, D. Ukena, 1995, Nuklearmedizin. Nuclear medicine.

2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography in target volume definition for radiotherapy of patients with non-small-cell lung cancer.

C. Rübe, M. Baumann, U. Nestle, 2002, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[Optimization of radiotherapy planning for non-small cell lung cancer (NSCLC) using 18FDG-PET].

U. Nestle, C. Kirsch, D. Ukena, 2002, Nuklearmedizin. Nuclear medicine.

[Drug-induced pulmonary diseases].

D. Ukena, 2007, Der Pneumologe.

Ciclesonide is more effective than budesonide in the treatment of persistent asthma.

C. Biberger, D. Ukena, V. Steinijans, 2007, Pulmonary pharmacology & therapeutics.

Comparison of early pulmonary changes in 18FDG-PET and CT after combined radiochemotherapy for advanced non-small-cell lung cancer: a study in 15 patients.

C. Rübe, M. Baumann, U. Nestle, 2002, Frontiers of radiation therapy and oncology.

[Value of positron emission tomography with 18-fluorodeoxyglucose (FDG-PET) in diagnosis of recurrent bronchial carcinoma].

D. Hellwig, C. Kirsch, G. Sybrecht, 2000, Pneumologie.

[Recommendations on the diagnosis of bronchial carcinoma. German Pneumology Society].

U. Gatzemeier, D. Ukena, H. Morr, 2000, Pneumologie.

Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma

L. Boulet, I. Naya, S. Centanni, 2004, Current medical research and opinion.

Chemotherapy in stage I+II non-small cell lung cancer.

D. Ukena, 2001, Lung cancer.

Bronchial and bronchovascular sleeve resection for treatment of central lung tumors.

H. Schäfers, T. Graeter, D. Ukena, 2000, The Annals of thoracic surgery.

[Extensive mediastinal staging in lung cancer--contra].

D. Ukena, 2009, Deutsche medizinische Wochenschrift.

[Pathological-anatomical diagnosis according to the German lung cancer guideline 2018].

R. Büttner, D. Ukena, K. Junker, 2018, Der Pathologe.

[Brain metastases of lung cancer: diagnostic accuracy of positron emission tomography with fluorodeoxyglucose (FDG-PET)].

D. Hellwig, C. Kirsch, G. Sybrecht, 1999, Medizinische Klinik.

[3H]xanthine amine congener of 1,3-dipropyl-8-phenylxanthine: an antagonist radioligand for adenosine receptors.

K. Jacobson, J. Daly, D. Ukena, 1986, Proceedings of the National Academy of Sciences of the United States of America.

[Quality of Care in Certified Lung Cancer Centers].

C. Kowalski, H. Hoffmann, D. Ukena, 2015, Pneumologie.

Shifting cancer care towards Multidisciplinarity: the cancer center certification program of the German cancer society

M. Beckmann, C. von Kalle, W. Stummer, 2017, BMC Cancer.

Effects of N-ethylmaleimide on adenosine receptors of rat fat cells and human platelets

E. Poeschla, D. Ukena, U. Schwabe, 1984, Naunyn-Schmiedeberg's Archives of Pharmacology.

Labelling of Ri adenosine receptors in rat fat cell membranes with (−)-[125iodo]N6-hydroxyphenylisopropyladenosine

M. Lohse, D. Ukena, G. Engel, 1984, Naunyn-Schmiedeberg's Archives of Pharmacology.

Xanthine derivatives as antagonists at A1 and A2 adenosine receptors

M. Lohse, D. Ukena, U. Schwabe, 1985, Naunyn-Schmiedeberg's Archives of Pharmacology.

Guanine nucleotide and cation regulation of radioligand binding to Ri adenosine receptors of rat fat cells

E. Poeschla, D. Ukena, U. Schwabe, 1984, Naunyn-Schmiedeberg's Archives of Pharmacology.

Functionalized congeners of 1,3-dipropyl-8-phenylxanthine: potent antagonists for adenosine receptors that modulate membrane adenylate cyclase in pheochromocytoma cells, platelets and fat cells.

K. Jacobson, J. Daly, D. Ukena, 1986, Life sciences.

Effects of enprofylline on A1 and A2 adenosine receptors.

D. Ukena, U. Schwabe, C. Schirren, 1985, European journal of pharmacology.

ADENOSINE RECEPTORS ON HEART MUSCLE

M. Lohse, D. Ukena, U. Schwabe, 1984, The Lancet.

Bronchial asthma: diagnosis and long-term treatment in adults.

D. Ukena, W. Niebling, Liat Fishman, 2008, Deutsches Arzteblatt international.

[Recommendations for the choice of inhalatory systems for drug prescription].

K. Rabe, T. Gessler, P. Haidl, 2001, Pneumologie.

Ra Adenosine receptors in human platelets

D. Ukena, U. Schwabe, E. Hüttemann, 1984, Naunyn-Schmiedeberg's Archives of Pharmacology.

Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.

S. Drechsler, D. Ukena, L. Faerber, 1994, Seminars in oncology.

Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nausea

M. Bangerter, S. Drechsler, M. Untch, 1997, Supportive Care in Cancer.

Cisplatin / etoposide (PE) followed by twice-daily chemoradiation (hfRT/CT) versus PE alone before surgery in stage III non-small cell lung cancer (NSCLC): A randomized phase III trial of the German Lung Cancer Cooperative Group (GLCCG).

C. Rübe, M. Semik, M. Thomas, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PAF-receptors on eosinophils: identification with a novel ligand, [3H]WEB 2086.

P. Barnes, G. Sybrecht, D. Ukena, 1989, Biochemical pharmacology.

Radioligand binding of antagonists of platelet‐activating factor to intact human platelets

P. Barnes, G. Sybrecht, D. Ukena, 1988, FEBS letters.

Beta2-Adrenergic Receptors on Eosinophils: Binding and Functional Studies

K. Chung, P. Barnes, C. Kroegel, 1990 .

[Therapy of asthma: anti-inflammatory effects of antileukotrienes].

D. Ukena, 1997, Medizinische Klinik.

[Asthma therapy: combination of topical glucocorticosteroids and theophylline].

D. Ukena, 1997, Medizinische Klinik.

Effect of theophylline and adenosine on eosinophil function.

K. Chung, P. Barnes, C. Kroegel, 1989, The American review of respiratory disease.

Functional Characteristics of Beta-Adrenergic Receptors of the Intact Eosinophil

K. Chung, P. Barnes, C. Kroegel, 1989 .

Characterization of PAF receptors on human neutrophils using the specific antagonist, WEB 2086 Correlation between receptor binding and function

G. Sybrecht, D. Ukena, G. Dent, 1989, FEBS letters.

The muscarinic M1·receptor·selective antagonist, telenzepine,

G. Sybrecht, D. Ukena, V. Steinijans, 2012 .

[3H]WEB 2086 labels platelet activating factor receptors in guinea pig and human lung.

P. Barnes, G. Sybrecht, D. Ukena, 1989, European journal of pharmacology.

[Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma].

R. Sakalauskas, D. Ukena, V. Steinijans, 1998, Pneumologie.

[Long-acting beta(2)-adrenoceptor agonists for asthma and COPD].

H. Magnussen, K. Rabe, D. Ukena, 1997, Medizinische Klinik.

Effect of nedocromil sodium on down-regulation of pulmonary beta-adrenoceptors.

P. Barnes, D. Ukena, I. Kioumis, 1989, Clinical science.

First-time treatment with steroids in bronchial asthma: comparison of the effects of inhaled beclomethasone and of oral prednisone on airway function, bronchial reactivity and hypothalamic-pituitary-adrenal axis.

T. Wagner, G. Sybrecht, D. Ukena, 1990, The European respiratory journal.

Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma

H. Sitter, H. Magnussen, K. Rabe, 2006, Pneumologie.

[Inhaled salmeterol or oral theophylline in nocturnal asthma?].

D. Ukena, 1997, Pneumologie.

[Therapy of nocturnal asthma: salmeterol versus nocturnal administration of retard theophylline--comparison of effectiveness and tolerance].

G. Sybrecht, D. Ukena, I. Koper, 1997, Pneumologie.

Management of chronic airway obstruction: Theophylline—Is it still necessary?

G. Sybrecht, D. Ukena, 2007, Lung.

Evidence for an A2 adenosine receptor in guinea pig lung

K. Klotz, D. Ukena, U. Schwabe, 1985, Naunyn-Schmiedeberg's Archives of Pharmacology.

[Prevention, diagnosis, therapy, and follow-up of lung cancer].

H. Kauczor, I. Petersen, C. Rübe, 2010, Pneumologie.

Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma.

R. Sakalauskas, D. Ukena, V. Steinijans, 1997, The European respiratory journal.

A phase I study of paclitaxel in combination with etoposide in patients with stage IIIB/IV non-small cell lung cancer (NSCLC).

L. Zell, G. Sybrecht, D. Ukena, 1998, Lung cancer.

Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstruction.

G. Sybrecht, D. Ukena, K. Rentz, 1995, Respiratory medicine.

[125I] N6-p-hydroxyphenylisopropyladenosine, a new ligand for Ri adenosine receptors

D. Ukena, H. Glossmann, D. Ferry, 1982, Naunyn-Schmiedeberg's Archives of Pharmacology.

[Amiodarone-induced pulmonary toxicity].

A. Heisel, H. Schieffer, D. Ukena, 1997, Medizinische Klinik.

Definition of subclasses of adenosine receptors associated with adenylate cyclase: interaction of adenosine analogs with inhibitory A1 receptors and stimulatory A2 receptors.

J. Daly, D. Ukena, R. Olsson, 1987, Canadian journal of physiology and pharmacology.

[Non-small cell lung cancer (NSCLC) stage IIIA/IIIB. A pilot study of neoadjuvant chemotherapy with paclitaxel and carboplatin].

H. Schäfers, H. Huwer, G. Sybrecht, 1997, Medizinische Klinik.

The muscarinic M1-receptor-selective antagonist, telenzepine, had no bronchodilatory effects in COPD patients.

G. Sybrecht, D. Ukena, V. Steinijans, 1993, The European respiratory journal.

Molecular probes for extracellular adenosine receptors.

K. Jacobson, J. Daly, D. Ukena, 1987, Biochemical pharmacology.

[Treatment of malignant pericardial effusion].

H. Schäfers, A. Heisel, H. Schieffer, 1997, Medizinische Klinik.

Non-xanthine heterocycles: activity as antagonists of A1- and A2-adenosine receptors.

K. Jacobson, J. Daly, D. Ukena, 1988, Biochemical pharmacology.

The protein kinase C activator phorbol‐12‐myristate‐13‐acetate enhances cyclic AMP accumulation in pheochromocytoma cells

E. Hollingsworth, J. Daly, D. Ukena, 1986, FEBS letters.

Adenosine receptors: development of selective agonists and antagonists.

K. Jacobson, J. Daly, D. Ukena, 1987, Progress in clinical and biological research.

Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial

C. Kropf-Sanchen, P. Schnabel, W. Engel-Riedel, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Analogs of caffeine: antagonists with selectivity for A2 adenosine receptors.

J. Daly, D. Ukena, W. Padgett, 1986, Life sciences.

Analogues of Adenosine, Theophylline, and Caffeine: Selective Interactions with A1 and A2 Adenosine Receptors

Kenneth A. Jacobson, John W. Daly, K. Jacobson, 1987 .

Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatin.

Michael Schroeder, Christian Schumann, C. Schumann, 2006, Clinical lung cancer.

Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non–small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung)

H. Müller-Huesmann, J. Bargon, M. Sebastian, 2021, Journal of immunotherapy.

N 6‐Substituted 9‐methyladenines: A new class of adenosine receptor antagonists

J. Daly, D. Ukena, D. Daly, 1987, FEBS letters.

A [3H]amine congener of 1,3‐dipropyl‐8‐phenylxanthine

K. Jacobson, J. Daly, D. Ukena, 1986, FEBS letters.

Adenosine receptor-blocking xanthines as inhibitors of phosphodiesterase isozymes.

G. Sybrecht, D. Ukena, C. Schudt, 1993, Biochemical pharmacology.

Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer

H. Kauczor, I. Petersen, C. Rübe, 2010, Pneumologie.

Demonstration of Ri-type adenosine receptors in bovine myocardium by radioligand binding

M. Lohse, D. Ukena, U. Schwabe, 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

A palliative accelerated irradiation regimen (PAIR) for advanced non-small-cell lung cancer (NSCLC).

U. Abel, U. Nestle, C. Nieder, 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

A palliative accelerated irradiation regimen for advanced non-small-cell lung cancer vs. conventionally fractionated 60 GY: results of a randomized equivalence study.

U. Abel, U. Nestle, C. Nieder, 2000, International journal of radiation oncology, biology, physics.

8-Aryl-and 8-cycloalkyl-1,3-dipropylxanthines: further potent and selective antagonists for A1-adenosine receptors.

J. Daly, D. Ukena, W. Padgett, 1988, Journal of medicinal chemistry.

Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.

J. Daly, D. Ukena, W. Padgett, 1989, Journal of medicinal chemistry.

Species differences in structure‐activity relationships of adenosine agonists and xanthine antagonists at brain A1 adenosine receptors

K. Jacobson, J. Daly, D. Ukena, 1986, FEBS letters.

[Surgical Therapy for Lung Cancer: Why it Should be Performed in High Volume Centres].

B. Passlick, H. Hoffmann, D. Ukena, 2019, Zentralblatt fur Chirurgie.

P1.01-82 Risk of Not Receiving 2nd Line Therapy is High in EGFR mt+ pts: Real World Data of Certified Lung Cancer Centers on Treatment Sequence in EGFR mt+ pts

M. Tiemann, L. Heukamp, D. Ukena, 2018, Journal of Thoracic Oncology.

Risk of not receiving 2nd line therapy is high in EGFR mt+ pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ pts.

M. Tiemann, L. Heukamp, D. Ukena, 2018 .

Effects of several 5′-carboxamide derivatives of adenosine on adenosine receptors of human platelets and rat fat cells

E. Böhme, D. Ukena, U. Schwabe, 1984, Naunyn-Schmiedeberg's Archives of Pharmacology.

Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy.

H. Schäfers, D. Hellwig, C. Kirsch, 2003, The Annals of thoracic surgery.

Shifting cancer care towards Multidisciplinarity: the cancer center certification program of the German cancer society

M. Beckmann, C. von Kalle, W. Stummer, 2017, BMC Cancer.

Synthesis of tritiated functionalized congeners of 1.3-dipropylxanthine having high affinity at adenosine receptors

K. Jacobson, J. Daly, D. Ukena, 1986 .

[Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version].

H. Kauczor, I. Petersen, C. Rübe, 2011, Pneumologie.

Characterization of [3H]phenobarbital binding to rat brain membranes

K. Klotz, M. Lohse, D. Ukena, 1984, Neuroscience Letters.

CHARACTERIZATION OF CH ] PHENOBARBITAL BINDING TO RAT BRAIN MEMBRANES

K. Klotz, D. Ukena, U. Schwabe, 2009 .

IL-2 in combination with IFN-αand 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial

M. Gramatzki, B. Metzner, D. Ukena, 2001, British Journal of Cancer.

[Management of Lung Abscess].

A. Marra, L. Hillejan, D. Ukena, 2015, Zentralblatt fur Chirurgie.

N6-substituted N-alkyladenosine-5'-uronamides: bifunctional ligands having recognition groups for A1 and A2 adenosine receptors.

J. Daly, D. Ukena, W. Padgett, 1986, Journal of medicinal chemistry.

[Recommendations on the therapy of bronchial carcinoma].

L. Freitag, M. Baumann, U. Gatzemeier, 2002, Pneumologie.

Tolerance, safety, and kinetics of the new antineoplastic compound dexniguldipine-HCl after oral administration: a phase I dose-escalation trial

G. Sybrecht, W. Wurst, D. Ukena, 2004, Cancer Chemotherapy and Pharmacology.

Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma

K. Rabe, P. Kardos, D. Berdel, 2006, Pneumologie.